Alto Neuroscience, Inc. - 10-Q Filing

Alto Neuroscience, Inc. reports Q3 2026 financial results featuring significant debt restructuring and ongoing clinical-stage research expenditures.

SEC EDGAR ·

Tickers: $ANRO

Read the full article at SEC EDGAR

More Regulatory news